 This is a study evaluating the safety and effectiveness of Combretastatin A4 Phosphate CA4P combined with the chemotherapy drugs, carboplatin and paclitaxel. The full treatment and observation time should be about 5 months. During this time the patient should receive 18 CA4P infusions and 6 carboplatin followed by paclitaxel treatments. Patients will be randomized into one of two CA4P dose-level groups in order to recommend a preferred dose-level for future studies. At least 2 dynamic contrast enhanced-magnetic resonance imaging DCE-MRI scans will be conducted to monitor the blood flow through the tumor before and after treatment with CA4P. 